

Jay Y Spiegel

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/713301/publications.pdf>

Version: 2024-02-01

32
papers

1,546
citations

516710

16
h-index

434195

31
g-index

32
all docs

32
docs citations

32
times ranked

1924
citing authors

#	ARTICLE	IF	CITATIONS
1	Recurrent Status Epilepticus in the Setting of Chimeric Antigen Receptor (CAR)-T Cell Therapy. <i>Neurohospitalist</i> , The, 2022, 12, 194187442110009.	0.8	2
2	Treating CAR-T relapses: check not checkmate. <i>Blood</i> , 2022, 139, 955-957.	1.4	2
3	Imagining the cell therapist: Future CAR T cell monitoring and intervention strategies to improve patient outcomes. <i>EJHaem</i> , 2022, 3, 46-53.	1.0	3
4	Severity of Cytokine Release Syndrome Influences Outcome After Axicabtagene Ciloleucel for Large B cell Lymphoma: Results from the US Lymphoma CAR-T Consortium. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2022, 22, 753-759.	0.4	6
5	Outcomes of Patients with Large B-cell Lymphoma Progressing after Axicabtagene Ciloleucel. <i>Blood</i> , 2021, 137, 1832-1835.	1.4	48
6	Molecular Imaging of Chimeric Antigen Receptor T Cells by ICOS-ImmunoPET. <i>Clinical Cancer Research</i> , 2021, 27, 1058-1068.	7.0	53
7	CD22-directed CAR T-cell therapy induces complete remissions in CD19-directed CAR ⁺ refractory large B-cell lymphoma. <i>Blood</i> , 2021, 137, 2321-2325.	1.4	51
8	Immune reconstitution and infectious complications following axicabtagene ciloleucel therapy for large B-cell lymphoma. <i>Blood Advances</i> , 2021, 5, 143-155.	5.2	92
9	CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial. <i>Nature Medicine</i> , 2021, 27, 1419-1431.	30.7	273
10	Incidence and risk factors associated with bleeding and thrombosis following chimeric antigen receptor T-cell therapy. <i>Blood Advances</i> , 2021, 5, 4465-4475.	5.2	28
11	Monitoring of Circulating Tumor DNA Improves Early Relapse Detection After Axicabtagene Ciloleucel Infusion in Large B-Cell Lymphoma: Results of a Prospective Multi-Institutional Trial. <i>Journal of Clinical Oncology</i> , 2021, 39, 3034-3043.	1.6	76
12	CD22-CAR T-Cell Therapy Mediates High Durable Remission Rates in Adults with Large B-Cell Lymphoma Who Have Relapsed after CD19-CAR T-Cell Therapy. <i>Blood</i> , 2021, 138, 741-741.	1.4	4
13	Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium. <i>Journal of Clinical Oncology</i> , 2020, 38, 3119-3128.	1.6	481
14	Molecular Imaging of Chimeric Antigen Receptor T Cells By ICOS-Immunopet. <i>Blood</i> , 2020, 136, 5-6.	1.4	3
15	Monitoring Measurable Residual Disease Using Peripheral Blood in Acute Lymphoblastic Leukemia: Results of a Prospective, Observational Study. <i>Blood</i> , 2020, 136, 22-23.	1.4	2
16	CD58 Aberrations Limit Durable Responses to CD19 CAR in Large B Cell Lymphoma Patients Treated with Axicabtagene Ciloleucel but Can be Overcome through Novel CAR Engineering. <i>Blood</i> , 2020, 136, 53-54.	1.4	28
17	Bleeding and Thrombosis Are Associated with Endothelial Dysfunction in CAR-T Cell Therapy and Are Increased in Patients Experiencing Neurologic Toxicity. <i>Blood</i> , 2020, 136, 32-33.	1.4	4
18	Circulating DNA for Molecular Response Prediction, Characterization of Resistance Mechanisms and Quantification of CAR T-Cells during Axicabtagene Ciloleucel Therapy. <i>Blood</i> , 2019, 134, 550-550.	1.4	13

#	ARTICLE	IF	CITATIONS
19	Phase I Trial Using CD19/CD22 Bispecific CAR T Cells in Pediatric and Adult Acute Lymphoblastic Leukemia (ALL). <i>Blood</i> , 2019, 134, 744-744.	1.4	42
20	Characteristics and Outcomes of Patients Receiving Bridging Therapy While Awaiting Manufacture of Standard of Care Axicabtagene Ciloleucel CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma: Results from the US Lymphoma CAR-T Consortium. <i>Blood</i> , 2019, 134, 245-245.	1.4	37
21	Identification of Two CAR T-Cell Populations Associated with Complete Response or Progressive Disease in Adult Lymphoma Patients Treated with Axi-Cel. <i>Blood</i> , 2019, 134, 779-779.	1.4	6
22	Characteristics and Outcomes of Patients Who Did Not Develop CRS after Axicabtagene Ciloleucel for Relapsed/Refractory Large B-Cell Lymphoma: Results from the US Lymphoma CAR-T Consortium. <i>Blood</i> , 2019, 134, 1583-1583.	1.4	3
23	Detectable Circulating Tumor DNA 28 Days after the CD19 CAR T-Cell Therapy, Axicabtagene Ciloleucel, Is Associated with Poor Outcomes in Patients with Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2019, 134, 884-884.	1.4	13
24	A phase I study of intravenous artesunate in patients with advanced solid tumor malignancies. <i>Cancer Chemotherapy and Pharmacology</i> , 2018, 81, 587-596.	2.3	66
25	Clinical Utility of Next-Generation Sequencing in the Management of Myeloproliferative Neoplasms: A Single-Center Experience. <i>HemaSphere</i> , 2018, 2, e44.	2.7	19
26	Phase I Experience with a Bi-Specific CAR Targeting CD19 and CD22 in Adults with B-Cell Malignancies. <i>Blood</i> , 2018, 132, 490-490.	1.4	43
27	Elevated Axicabtagene Ciloleucel (CAR-19) Expansion By Immunophenotyping Is Associated with Toxicity in Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2018, 132, 576-576.	1.4	4
28	Axicabtagene Ciloleucel (Axi-cel) CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma: Real World Experience. <i>Blood</i> , 2018, 132, 91-91.	1.4	81
29	Target Antigen Downregulation and Other Mechanisms of Failure after Axicabtagene Ciloleucel (CAR19) Therapy. <i>Blood</i> , 2018, 132, 4656-4656.	1.4	11
30	Validation of the NCCN-IPI in both <i>de novo</i> and transformed diffuse large B cell lymphoma. <i>Leukemia and Lymphoma</i> , 2017, 58, 214-217.	1.3	4
31	Impact of genomic alterations on outcomes in myelofibrosis patients undergoing JAK1/2 inhibitor therapy. <i>Blood Advances</i> , 2017, 1, 1729-1738.	5.2	48
32	A phase I study of intravenous artesunate (IV AS) in patients with solid tumors.. <i>Journal of Clinical Oncology</i> , 2015, 33, 2535-2535.	1.6	0